Startseite>>Signaling Pathways>> GPCR/G protein>> Ghrelin Receptors>>PF 04628935

PF 04628935

Katalog-Nr.GC50425

Potent ghrelin receptor inverse agonist

Products are for research use only. Not for human use. We do not sell to patients.

PF 04628935 Chemische Struktur

Cas No.: 1383719-97-8

Größe Preis Lagerbestand Menge
5 mg
117,00 $
Auf Lager
25 mg
450,00 $
Auf Lager

Tel:(909) 407-4943 Email: sales@glpbio.com


Kundenbewertungen

Basiert auf Kundenrezensionen.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description of PF 04628935

Potent ghrelin receptor inverse agonist (IC50 = 4.6 nM). Orally bioavailable and exhibits reasonable brain penetration.

Kung et al (2012) Identification of spirocyclic piperidine-azetidine inverse agonists of the ghrelin receptor. Bioorg.Med.Chem.Lett. 22 5410 PMID:22677316

Chemical Properties of PF 04628935

Cas No. 1383719-97-8 SDF
Canonical SMILES ClC1=C(CN2CC3(CCN(C(CC4=CN(C=C(C)S5)C5=N4)=O)CC3)C2)C=CC(N6N=CC=N6)=C1
Formula C24H26ClN7OS M.Wt 496.03
Löslichkeit Soluble in DMSO Storage Store at -20°C
General tips Please select the appropriate solvent to prepare the stock solution according to the solubility of the product in different solvents; once the solution is prepared, please store it in separate packages to avoid product failure caused by repeated freezing and thawing.Storage method and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored at -20°C, please use it within 1 month.
To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time.
Shipping Condition Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request.

Complete Stock Solution Preparation Table of PF 04628935

Prepare stock solution
1 mg 5 mg 10 mg
1 mM 2.016 mL 10.08 mL 20.1601 mL
5 mM 0.4032 mL 2.016 mL 4.032 mL
10 mM 0.2016 mL 1.008 mL 2.016 mL
  • Molaritätsrechner

  • Verdünnung-Rechner

  • Molecular Weight Calculator

Gewicht
=
Konzentration
x
Inhalt
x
MW*
 
 
 
**Bei der Herstellung von Stammlösungen ist immer das chargenspezifische Molekulargewicht von

Berechnen

In vivo Formulation Calculator (Clear solution) of PF 04628935

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.

Product Documents

Quality Control & SDS

View current batch:

Bewertungen

Review for PF 04628935

Average Rating: 5 ★★★★★ (Based on Reviews and 12 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for PF 04628935

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.